| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2008, Vol. 112, No. 12, pp. 4458-4465. Prepublished online as a Blood First Edition Paper on August 6, 2008; DOI 10.1182/blood-2007-07-102947.
Submitted July 24, 2007
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United States * Corresponding author; email: dclapp{at}iupui.edu.
Fanconi anemia (FA) is a complex genetic disorder characterized by congenital abnormalities, bone marrow failure, and myeloid malignancies. Identification of 13 FA genes has been instrumental to explore gene transfer technologies aimed at correction of autologous FA deficient stem cells. To date, three human FA stem cell gene therapy trials with standard 4-day transduction protocols using gammaretroviral vectors failed to provide clinical benefit. In addition, 2-4 day ex vivo manipulation of bone marrow from mice containing a disruption of the homologue of human FANCC (Fancc) results in a time-dependent increase in apoptosis and a risk for malignant transformation of hematopoietic cells. Here, we show that a 14-hour transduction period allows a foamyviral vector construct expressing the human FANCC cDNA to efficiently transduce murine FA stem cells with 1-2 proviral integrations per genome. Functionally, the repopulating activity of Fancc-/- stem cells from reconstituted mice expressing the recombinant FANCC transgene was comparable to wildtype controls. Collectively, these data provide evidence that short term transduction of c-kit+ cells with a foamyviral vector is sufficient for functional correction of a stem cell phenotype in a murine FA model. These data could have implications for future gene therapy trials for FA patients.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||